ViaCell is a stem cell research company, ticker symbol VIAC. VIAC recently IPO'ed on Nasdaq at $7 on January 21, 2005.
They dedicated to enabling the widespread application of human cells as medicine in the treatment of human disease.
The company is partially owned by AMGEN. ViaCell is also conducting stem cell research with Genzyme Corporation on diabetes. Scientists from various universities were involved in the creation of ViaCell. Smart group.
ViaCell currently generates revenue thru cord blood used in bone marrow transplants. But they are looking towards future development in cellular medicine products with the first clinical trial of their product line, CB001, a highly concentrated and purified population of stem cells.
The CB001 was originally developed as a substitute for bone marrow and other hematopoietic stem cell transplants.
viacellinc.com |
